Expression of fructose 1,6 bisphosphate aldolase in transgenic plants
AssigneeMonsanto Technology LLC
InventorsGerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
Life of this patent
Estimating the term…
Loading patent…
AssigneeMonsanto Technology LLC
InventorsGerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
Estimating the term…
Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
In a method for the processing of potatoes into fries or chips, the improvement comprising, utilizing a potato that overexpresses a prokaryotic fructose 1,6 bisphosphate aldolase transgene providing a higher solids uniformity in such potato.
Dependencies are inferred from the claim text.